University of Ioannina
Σχεδιασμός, σύνθεση και βιολογικός έλεγχος νέων οργανικών - βιοδραστικών ενώσεων μικρού μοριακού βάρους ως ανταγωνιστών της τριφωσφορικής αδενοσίνης (ΑΤΡ)
Abstract
dc:descriptionProtein kinases are enzymes that play pivotal role in cell functions regulating many signal pathways by inducing ATP phosphorylation. Dysregulation of protein kinase and their receptors activity has been related to various diseases, including Chronic Myeoid Leukemia. Inhibition of these pathological protein kinases through small molecular weight compounds that compete the ATP binding site in the kinase active core is found to contribute in the treatment of the disease symptoms. For this reason, there is great interest in the scientific community for the synthesis and development of new more potent protein kinase inhibitors, acting selectively in the pathological protein kinase. Imatinib (Gleevec) is the first selective inhibitor who antagonizes the ATP binding site in the pathological Bcr-Abl tyrosine kinase in the treatment against Chronic Myeloid Leukemia (CML). Nilotinib was designed as a second generation selective Bcr-Abl kinase inhibitor and exhibits greater inhibitory activity compared to Imatinib.Furthermore, Osimertinib was granted accelerated approval by Food and Drug Administration (FDA) for the treatment of patients with non-small cell lung cancer. New compounds, Nilotinib analogues/derivatives, were synthesized in the laboratory, as a result of molecular modeling and it is possible to act more effectively on the protein kinases targets, aiming at their selective inhibition. These modifications on the original pharmaceutical compound were targeted and were about the last phenyl ring, where the natural amino acid proline was attached. In addition, in some cases both the benzene and imidazole rings of Nilotinib were completely eliminated and replaced by substituted benzene rings. Some of these compounds were evaluated for their antiplatelet-antithrombotic activity. Also, an optimized synthetic approach for the synthesis of Osimertinib has been developed. The yield of this convergent experimental route reaches 68%,which is significantly higher than that obtained when using the methodology established by Astra Zeneca, whose efficiency is only up to 8%. Based on molecular modeling we designed to synthesize new Osimertinib’s analogues as potent protein kinase inhibitors. The modifications are focused on the indole ring, which was substituted by isosteric structures, called aza-indoles. Their synthesis is in progress and is carried out with the optimized methodology developed in the laboratory. All new compounds, final and intermediate, were fully characterized (1H NMR, 13C NMR, HRMS).
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Voulgari, Pinelopi
- Βούλγαρη, Πηνελόπη
Subjects
dc:subject × 22- Καρκίνος
- Νιλοτινίβη
- Οσιμερτινίβη
- Πρωτεϊνικές κινάσες
- Αναστολείς πρωτεϊνικών κινασών
- Υποδοχέας του επιδερμικού αυξητικού παράγοντα
- Στοχευμένη θεραπεία
- Οργανική σύνθεση
- Cancer
- Nilotinib
- Osimertinib
- Protein kinases
- Protein kinase inhibitors
- Epidermal growth factor receptor
- Targeted therapy
- Organic synthesis
- Χημεία
- Φυσικές Επιστήμες
- Οργανική χημεία
- Chemical Sciences
- Natural Sciences
- Organic Chemistry
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/49913